A federal judge in Delaware gave final approval Tuesday to a $9 million class-action settlement in Hartig Drug Co.’s antitrust suit against Allergan, after an appeals court in 2016 revived claims that Allergan had tried to suppress generic versions of its eye-care products.

The ruling, from U.S. District Senior Judge Joseph F. Bataillon of the District of Delaware, brought an end to nearly four and a half years of litigation in the product-hopping case, which had been closely watched by the pharmaceutical industry.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]